American Society of Hematology

Fig. 7.

$Fig. 7. P1218-specific CTLs recognize endogenously presented CD45. / (A) Cytotoxicity against the myeloma cell line U-266. (Panels Ai-iv) FACS analysis of expression of HLA-A2 (i,iii) and CD45 (ii,iv) in sorted CD45− (i-ii) and CD45+ (iii-iv) fractions. (Panel Av) Cytotoxicity of P1218-specific CTL line 2 against the sorted CD45− and CD45+ fractions. Results are shown as the means ± SDs of 3 experiments performed in triplicate. (B) Cytotoxicity against 293 cells stably transfected with CD45. (Panels Bi-iv) FACS analysis of expression of HLA-A2 (i, iii) and CD45 (ii, iv) in wild-type 293 cells (i-ii) and 293 cells stably transfected with CD45 (iii-iv). (Panel Bv) Cytotoxicity of P1218-specific CTL line 2 against these targets. Results are shown as the means ± SDs of triplicate wells in a representative experiment.$

P1218-specific CTLs recognize endogenously presented CD45.

(A) Cytotoxicity against the myeloma cell line U-266. (Panels Ai-iv) FACS analysis of expression of HLA-A2 (i,iii) and CD45 (ii,iv) in sorted CD45⁻ (i-ii) and CD45⁺ (iii-iv) fractions. (Panel Av) Cytotoxicity of P1218-specific CTL line 2 against the sorted CD45⁻ and CD45⁺ fractions. Results are shown as the means ± SDs of 3 experiments performed in triplicate. (B) Cytotoxicity against 293 cells stably transfected with CD45. (Panels Bi-iv) FACS analysis of expression of HLA-A2 (i, iii) and CD45 (ii, iv) in wild-type 293 cells (i-ii) and 293 cells stably transfected with CD45 (iii-iv). (Panel Bv) Cytotoxicity of P1218-specific CTL line 2 against these targets. Results are shown as the means ± SDs of triplicate wells in a representative experiment.

This Feature Is Available To Subscribers Only